

IGI LABORATORIES, INC

Form 3

March 26, 2015

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â Celentano John E

(Last) (First) (Middle)

2. Date of Event Requiring Statement

(Month/Day/Year)

03/17/2015

3. Issuer Name and Ticker or Trading Symbol
IGI LABORATORIES, INC [IG]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

☒ Director ☐ 10% Owner
☐ Officer ☐ Other
(give title below) (specify below)

C/O IGI LABORATORIES,
INC.,Â 105 LINCOLN
AVENUE

(Street)

BUENA,Â NJÂ 08310

(City) (State) (Zip)

6. Individual or Joint/Group
Filing(Check Applicable Line)
☒ Form filed by One Reporting
Person
☐ Form filed by More than One
Reporting Person

Table I - Non-Derivative Securities Beneficially Owned1. Title of Security
(Instr. 4)2. Amount of Securities
Beneficially Owned
(Instr. 4)

3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)

4. Nature of Indirect Beneficial
Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.**

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)1. Title of Derivative
Security
(Instr. 4)2. Date Exercisable and
Expiration Date
(Month/Day/Year)Date Exercisable Expiration
Date3. Title and Amount of
Securities Underlying
Derivative Security
(Instr. 4)Title Amount or
Number of4. Conversion
or Exercise
Price of
Derivative
Security5. Ownership
Form of
Derivative
Security:
Direct (D)6. Nature of Indirect
Beneficial
Ownership
(Instr. 5)

Edgar Filing: IGI LABORATORIES, INC - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	03/17/2016 ⁽¹⁾	03/17/2025	Common Stock	15,000	\$ 8.19	D	Â
Stock Option (Right to Buy)	03/17/2016 ⁽²⁾	03/17/2025	Common Stock	15,000	\$ 8.19	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Celentano John E C/O IGI LABORATORIES, INC. 105 LINCOLN AVENUE BUENA, NJ 08310	Â X	Â	Â	Â

Signatures

/s/ John
Celentano

03/26/2015

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) These securities were issued as part of the Issuer's director compensation program pursuant to the 1999 Director Stock Option Plan. The options shall vest fully on the first anniversary of the grant date.

(2) These securities were issued as part of the Issuer's director compensation program pursuant to the 2009 Equity Incentive Plan, as amended. The options shall vest fully on the first anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.